Pembrolizumab, a programmed cell death protein (PD-1) inhibitor, has shown promise in treating bladder cancer, particularly in cases with high programmed death-ligand 1 (PD-L1) expression and relapsed tumors, with the Keynote-057 study revealing a 17% rate of lasting complete response after 12 months (11). The gene discussed is CD274; the disease is urinary bladder carcinoma.